Summary
58 / 100 · Bulios Score
What speaks for it
- It beat profit estimates 8 times in the last 8 quarters.
- It passes 8 of the 9 points of the Piotroski financial health test.
What to watch
- Repaying its net debt would take 4.4 years of operating profit.
- Out of every 100 USD of revenue, only 4.1 USD is left as net profit.
- It earns only 5.0 USD a year on every 100 USD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 24.4 USD for 1 USD of yearly profit. Over the last five years it was 42.4 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 9.8% a year over 5 years. Over the last 3 years it grew by 9.5% a year. For the next fiscal year analysts expect revenue to fall by 0.6%.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 45 USD
- Research and development 4.4 USD
- Sales and administration 40 USD
- Taxes and other 6.7 USD
- Net profit 4.1 USD
Net profit, industry median (Medical - Devices) 6.9 USD
Out of every 100 USD of revenue, 4.1 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 6.2 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 0.43%
- Paid out of profit
- 11%
You receive $0.20 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Neutral- Buy 7
- Hold 13
- Sell 1
Today's price within the analysts' price targets
The average target of $37.5 is 23% below today's price. 33% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- General Surgery 58%
- Orthopedic Surgery 42%
By region
- UNITED STATES 56%
- EMEA 19%
- Asia Pacific 15%
- Americas (excluding the United States) 9.2%
General Surgery brings in 58% of revenue.
Segments in detail